| Name | Title | Contact Details |
|---|
RDMD`s mission is to empower patients and communities to accelerate the development of treatments for rare diseases of all kinds.
PAR Management is a Newton, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Adgero Biopharmaceuticals Holdings, Inc. is a privately-held biopharmaceutical company focused on building a pipeline by advancing its proprietary late stage photodynamic therapy ("PDT") platform with broad utility for the treatment of serious oncology indications. Its lead product candidate, REM-001 Therapy, has demonstrated promising safety and efficacy in four Phase 2/3 clinical studies in patients with cutaneous metastatic breast cancer ("CMBC") who have failed radiation therapy. Use of Adgero`s existing data or the completion of a Phase 3 trial in individuals with CMBC could lead to approval of REM-001 Therapy.
The National Institutes of Health (NIH) is the largest biomedical research agency in the world, conducting research in its own laboratories, supporting the research of non-Federal scientists in universities, medical schools, hospitals, and research ins...
RNAimmune is a biotechnology startup in the field of messenger RNA (mRNA) technology with more than 20 years expertise in handling and optimizing this versatile molecule for medical purposes. The principle of RNAimmune`s proprietary technology is the use of mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. The company applies its technologies for the development of cancer therapies, antibody therapies, the treatment of rare diseases, and prophylactic vaccines.